Organic Revenue Growth
Total company organic revenue growth, which excludes currency and acquisition effects, was 9.0% in Q2 FY2026, with CAG organic growth at 8.7% and Water at 13.0%.
At the archive date, IDEXX LABORATORIES INC /DE was expected to release its Q3 2026 10-Q filing on November 2, 2026, before market open. Last quarter: IDEXX Laboratories posted higher Q2 FY2026 revenue and net income, led by strong CAG diagnostics recurring sales and broad margin improvement.
EPS Estimate
$3.81
Revenue Estimate
$1.21B
Analyst consensus captured from Finnhub and Financial Modeling Prep. This archived preview is no longer updated with later results; see the IDXX page for retained reports.
Drawn from management commentary in the Q2 2026 10-Q:
Total company organic revenue growth, which excludes currency and acquisition effects, was 9.0% in Q2 FY2026, with CAG organic growth at 8.7% and Water at 13.0%.
CAG instrument revenue fell 19.5% reported, primarily due to lower placements of the IDEXX inVue Dx Analyzer compared to its broad commercial availability in the second quarter of 2025.
The 140-basis-point increase in consolidated gross margin to 64.0% reflected higher-margin consumable and lab volume growth, lower premium instrument mix, operational productivity, and net price realization.
Revenue
$1.22B
+9.66% YoY
EPS (Diluted)
$4.27
+17.63% YoY
Gross Margin
64.0%
+1.4 pts YoY
Operating Income
$425.57M
+14.08% YoY
Add IDXX to your watchlist to keep its archived reports easy to find. New filing alerts are no longer sent.